Savara Inc (NASDAQ:SVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Savara Inc (NASDAQ:SVRA) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.83.

A number of equities analysts recently weighed in on SVRA shares. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company began coverage on shares of Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target for the company.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cibc World Markets Corp acquired a new stake in shares of Savara in the 4th quarter valued at $33,000. XTX Topco Ltd acquired a new stake in shares of Savara in the 4th quarter valued at $34,000. Ameriprise Financial Inc. acquired a new stake in shares of Savara in the 4th quarter valued at $37,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Savara in the 4th quarter valued at $41,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Savara in the 4th quarter valued at $48,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

NASDAQ:SVRA opened at $2.61 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a market capitalization of $447.93 million, a P/E ratio of -6.07 and a beta of 0.60. The company has a 50 day moving average price of $2.75 and a 200 day moving average price of $3.36. Savara has a fifty-two week low of $2.26 and a fifty-two week high of $5.34.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.